The Operator Led Evolution in European Healthcare M&A: The Rise of Founder Bankers in HealthTech, MedTech, FemTech and Healthcare AI

Nelson Advisors
2 hours ago
16 min read

Executive Summary

European healthcare M&A is undergoing a structural transformation that extends well beyond deal volumes and capital flows. The defining shift of the 2025–2026 cycle is not macroeconomic, it is epistemological: the question of who is best qualified to advise on the sale, acquisition and strategic positioning of healthcare technology assets has been fundamentally reopened.

For three decades, the architecture of healthcare M&A advisory was dominated by generalist bulge-bracket institutions, Goldman Sachs, J.P. Morgan, Morgan Stanley, Rothschild, whose authority derived from balance-sheet capability, broad institutional relationships and league-table prestige.

In 2026, that architecture remains intact for large-cap, cross-border mega-deals exceeding €500 Million. But for the far larger universe of founder-led, venture-backed and growth-stage HealthTech, MedTech, FemTech and Healthcare AI companies, the middle market that generates the majority of European deal volume, a new class of advisor has emerged and, in many sub-sectors, taken primacy.

They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.

This report analyses the structural drivers of this advisory evolution, the anatomy of the Founder Banker archetype, the market dynamics reinforcing its ascendancy across HealthTech, MedTech, FemTech and Healthcare AI, and the strategic outlook for founders, investors and acquirers navigating this new landscape.

Part I: The Great Rationalisation — Macroeconomic Context for Advisory Evolution From Speculative Exuberance to Industrial Maturity

The European HealthTech and MedTech market entered 2026 in a phase termed the "Great Rationalisation", a structural recalibration away from the venture-subsidised experimentation of 2019–2022 toward a disciplined, metrics-driven era of industrial maturity.

The decade of cheap capital that enabled a proliferation of fragmented "point solutions", single-feature apps, unvalidated clinical tools and consumer wellness platforms with limited integration into healthcare pathways, is over.

The post-pandemic valuation corrections of 2023 acted as a clearing event. Investors who had tolerated "growth at all costs" narratives were confronted with portfolio companies that had burned through capital without achieving clinical validation, reimbursement traction or sustainable unit economics. The result was a decisive shift in the criteria by which healthcare technology assets are valued: away from raw revenue growth toward clinical utility, regulatory resilience, EBITDA generation and integration into existing care pathways.

This transition did not reduce market activity, it redirected it. Global healthcare M&A deal value rose 38% to $546.7 Billion in 2025, one of the strongest years since the post-pandemic peak, even as overall deal volumes declined modestly. European healthcare PE deal value reached approximately $80.9 Billion in 2025, up from $59.9 Billion in 2024. The character of this activity changed: fewer transactions completed at higher average values, reflecting a concentration of capital in fewer but larger, high-conviction assets.

The Bifurcation Dynamic

The most striking feature of the current M&A environment is a bifurcation between volume and value and between asset categories. On one side: premium AI-native platforms, value-based care companies, MDR/IVDR-certified MedTech devices and clinical-grade data systems commanding revenue multiples of 6x–8x and EBITDA multiples of 15x–18x. On the other: undifferentiated SaaS tools, unprofitable point solutions, and consumer wellness apps trading at 2x–4x revenue or entering distressed M&A processes.

This bifurcation is the economic logic behind the Founder Banker's ascendancy. When every healthcare technology asset looked like a growth story in 2021, financial engineering was sufficient advisory value.

In 2026, when an acquirer must distinguish between a genuinely validated clinical AI platform and a statistically impressive but operationally fragile tool, the intellectual currency is domain fluency and that currency is disproportionately held by advisors who have lived the journey themselves.

Private Equity as Volume Engine

While strategic M&A attracts the headline transactions, Private Equity (PE) remains the dominant volume driver in European healthcare. European sponsor buyout deal value surged 276% year-to-date in 2025 compared to 2024, reflecting both accumulated dry powder (approximately $2.5 Trillion globally) and increasing pressure to deploy capital from the 2019–2021 vintage. PE portfolios contain a significant backlog of long-held assets requiring exit, making 2026 a year disproportionately shaped by exits rather than new platform formation.

The PE consolidation playbook has evolved beyond simple platform buyouts. Add-on acquisitions, secondary buyouts, and continuation funds are the dominant structural mechanisms, as sponsors build pan-European champions across dental, fertility, ophthalmology and veterinary services before eventual strategic exits. Specialist advisors who understand both the operational reality of these roll-up strategies and the buyer psychology of PE exits are in disproportionate demand.

Part II: The Anatomy of the Founder Banker, A New Professional Archetype

The Founder Banker is defined by a career trajectory that generalist investment banking cannot produce through its traditional analyst-to-managing-director pipeline. These advisors have personally experienced the full lifecycle of company-building: ideation, fundraising, product development, clinical validation, regulatory navigation, commercial scaling and, ultimately, an exit transaction.

They carry what is described as "operational empathy", an ability to understand, and critically to credibly communicate, the anxieties, trade-offs and ambitions of a founder navigating their first major liquidity event.

The comparative profile versus the traditional investment banker is materially different:

Feature	Traditional Investment Banker	Founder Banker
Career Path	Linear: Analyst → Associate → VP → MD	Non-linear: Founder → Exit → Strategic Advisor
Core Value Proposition	Financial engineering; institutional market access	Operational empathy; technical fluency; founder credibility
Advisory Philosophy	Transactional; prestige-driven; process-oriented	Relationship-driven; "Founders for Founders"
Diligence Focus	Top-line growth; market share; financial ratios	Clinical utility; regulatory resilience; unit economics
Technical Depth	Broad but generalist across sectors	Deep vertical specialisation (AI, MDR, NHS procurement)
Exit Psychology	Process management; information memorandum	Empathy with founder motivations; managing valuation resets

The Nelson Advisors Case Study

The most visible embodiment of the Founder Banker model in European HealthTech is Nelson Advisors, a London-based boutique founded by Lloyd Price and Paul Hemings, both of whom are former healthcare technology entrepreneurs with successful exits.

Lloyd Price brings over 25 years in consumer internet and HealthTech, most notably founding Zesty, a patient engagement platform that navigated complex NHS procurement frameworks before being acquired by Induction Healthcare Group PLC (FTSE:INHC) in 2020. His experience of integrating with hospital legacy systems, navigating clinical pathways, and managing the expectations of a public-company acquirer provides direct operational credibility in advising clients facing analogous exits. Price is also a Health Executive in Residence at UCL's Global Business School for Health and regularly guest lectures at Oxford, Cambridge and IESE Business School Barcelona.

Paul Hemings combines senior investment banking experience at Credit Suisse (over $50 Billion in M&A) and Invesco with entrepreneurial experience as co-founder of Neutrally, a metabolic health venture, providing direct founder credibility alongside institutional financial engineering capability. His dual profile, having been both the banker structuring complex cross-border transactions and the founder making the sale decision, is a rare combination that Nelson Advisors explicitly markets as the defining differentiator of their "Founders advising Founders" model.

Nelson Advisors team also includes analysts and directors with backgrounds from Rothschild, Citi, Morgan Stanley, ETH Zurich, Johnson & Johnson and Bristol Myers Squibb, reflecting a deliberate strategy of combining traditional investment banking rigour with healthcare operational depth.

The Broader Ecosystem of Specialist Boutiques

Nelson Advisors is the most explicitly "Founder Banker" firm in European HealthTech, but it operates within a broader ecosystem of specialist boutiques that collectively challenge generalist hegemony in the mid-market:

Arma Partners — independent advisor to the digital economy with a sophisticated Digital Health and Healthcare AI practice, widely cited for its depth in Health IT and SaaS-in-healthcare
Clipperton — Paris-headquartered European tech specialist bank with a fast-growing Digital Health and SaaS-in-healthcare franchise, frequently advising venture-backed health platforms on growth capital and strategic exits (e.g. Hublo, DentalMonitoring)
ConAlliance — healthcare-only M&A advisor with a strong European MedTech footprint, increasingly active across digital and technology-enabled healthcare assets
TH Healthcare & Life Sciences — partner-led healthcare M&A advisor working across Europe with private equity and VC-backed digital health and health services technology
WG Partners — London-based life sciences boutique with over £8.4 billion in completed transactions and an international practice spanning UK, Europe, USA, Asia and Australia
Van Lanschot Kempen (formerly Kempen & Co) — premier pan-European specialist investment bank in life sciences and healthcare, with particular strength in biotech and diagnostics

These firms have collectively taken the primary advisory role for founder-led exits in the €10M–€500M transaction range, the segment that constitutes the majority of European HealthTech deal volume.

Part III: Market Dynamics Driving the Founder Banker's Ascendancy, Regulatory Darwinism as Deal Catalyst

Perhaps the most powerful structural force driving Founder Banker demand in 2026 is what analysts are calling "Regulatory Darwinism", the use of EU regulatory architecture as a competitive weapon that forces consolidation.

The convergence of three regulatory frameworks is creating an unprecedented compliance burden:

Regulation	Milestone	M&A Implication
EU AI Act	Full enforcement, early 2026	Mandatory "glass box" interpretability; audit-ready AI systems required
EU MDR / IVDR	Class III deadline, May 2026	MDR certificates become primary financial assets and key valuation levers
EUDAMED	Mandatory registration, May 2026	Registration prerequisite for exit; competitive intelligence platform

The costs of Notified Body certification under MDR/IVDR and the compliance requirements of the EU AI Act are untenable for undercapitalised standalone SMEs, driving them into the arms of larger strategic acquirers who possess the necessary regulatory infrastructure.

Acquirers are explicitly purchasing smaller firms to bypass multi-year regulatory bottlenecks and secure immediate market access, a pattern described as "compliance-driven M&A". Advisors who understand the regulatory valuation mechanics, how to price a CE mark, an AI Act audit trail, or an IVDR certificate, command a significant premium over generalists who view compliance as a checkbox rather than a financial asset.

The EU AI Act imposes specific obligations on high-risk medical AI systems that materially affect advisory practice: mandatory "glass box" interpretability under Articles 13 and 14 means that investors are rigorously avoiding "black box" AI models in 2026, favouring transparent architectures that satisfy both regulatory requirements and acquirer diligence standards. Founder Bankers, who have typically navigated these frameworks with their own products, are uniquely positioned to translate regulatory exposure into commercial opportunity or risk during transaction processes.

The AI Premium in Valuation

Healthcare AI has become the single most powerful driver of valuation premiums across European HealthTech. Companies with proprietary algorithms, rigorous clinical validation and deep workflow integration are commanding EV/Revenue multiples of 6x–8x, versus 4x–6x for general HealthTech SaaS. Capital is concentrating around AI-powered diagnostics, ambient clinical intelligence, and research acceleration tools, which jointly captured the majority of AI funding in H1 2025.

This "AI premium" is no longer theoretical, it is directly visible in transaction rationales, where strategic acquirers and PE sponsors explicitly target AI-native platforms to modernise legacy portfolios. However, the spread between premium and average assets has widened dramatically, and distinguishing genuine clinical AI from AI-washed marketing requires precisely the technical fluency that Founder Bankers bring.

The "Rule of 40", where the sum of a company's revenue growth rate and EBITDA margin must exceed 40%, has become the new benchmark for premium multiples, replacing the growth-at-all-costs metrics of earlier cycles. In Q4 2025, each 10-point improvement in a company's Rule of 40 score was associated with approximately a 1.1x increase in EV/Revenue multiple.

The Series B+ Capital Gap and Transatlantic Flows

A defining feature of the 2025–2026 period is the intensity of transatlantic capital flows into European HealthTech. US corporate and growth funds participated in 62% of late-stage European deals in 2025, a triple increase from 2023 levels. This activity is helping bridge the historical "Series B+ Gap" that has constrained European founders' ability to raise large late-stage rounds domestically.

Notable transactions illustrate the trend: the $900 Million Series E for Finnish health-tech company Ōura and the $600 Million strategic round for UK-based Isomorphic Labs demonstrate that US capital is actively targeting European innovators who have already navigated the stringent EU regulatory environment, viewing them as "de-risked" assets ready for global deployment. Europe's digital health funding jumped 82% year-on-year to $2.0 Billion in Q1 2025, its second-highest quarterly total on record.

For advisors, transatlantic cross-border work requires a dual fluency: understanding how US acquirers (from Alphabet to UnitedHealth to Philips) evaluate European assets, what regulatory questions they ask, how NHS or European public payer relationships translate into US strategic value, and how valuation gaps between US and European markets can be bridged. Founder Bankers who have managed cross-border scaling journeys are naturally positioned to navigate this translation.

Part IV: Sub-Sector Dynamics, HealthTech and Digital Health

European digital health funding increased by 52% year-on-year in H1 2025, reaching $3.4 Billion across 182 deals. The overall HealthTech M&A deal volume in H1 2025 reached 277 deals, projecting a full-year total well above the 467 deals recorded in 2024, with disclosed deal value reaching $10.3 Billion in H1 2025 and on pace to surpass the 2024 total of $19.2 Billion.

The most valued sub-segments are AI-driven clinical decision support, EHR integration platforms and value-based care infrastructure. The shift away from B2C consumer health toward B2B enterprise and NHS/EU health system deployments has been decisive, acquirers reward assets with demonstrable ROI for payers, not consumer engagement metrics.

Vendor sprawl fatigue among hospital CIOs is driving demand for integrated platforms over point solutions, creating a market structure that rewards consolidation advisors.

MedTech

Global MedTech deal value surged to $97.6 billion in 2025 — the highest level in over a decade, driven by three mega-deals, though overall deal count remained below historical norms at 46 announced deals through November. The European MedTech landscape is defined by surgical robotics maturation, AI-driven medical imaging, and the compliance-driven consolidation wave triggered by MDR/IVDR.

Surgical robotics has transitioned from experimental to challenger platforms seeking global expansion. Companies including CMR Surgical (Versius, $1Bn+ total funding), Noah Medical (Galaxy Lung System, $400M) and Distalmotion (Dexter Hybrid, $300M) represent European innovators in active pursuit of strategic partnerships and acquisition processes.

Medical imaging and diagnostics saw venture investment reach $19.1 Billion in 2024, with acquirers focusing on AI tools that automate patient episode management from intake through treatment.

The advisory challenge in MedTech is distinct from Software: technical diligence on hardware, clinical evidence packages, Notified Body relationships and post-market surveillance data require advisors who can speak the language of regulatory bodies, clinicians and financial buyers simultaneously, a rare combination that favours specialists over generalists.

FemTech

By early 2026, FemTech had evolved from a niche sub-sector into a major pillar of global healthcare acquisition strategy. The European FemTech market reached €2.4 Billion in 2024 and is projected to nearly quadruple to €9.7 Billion by 2033, growing at approximately 16% CAGR. The sector has attracted over £480 Million in investment funding in the UK alone, growing at 30%.

The McKinsey 2024 report estimated that improving women's health outcomes could add £1 Trillion to the global economy by 2040, a macro-economic argument that has catalysed strategic acquirer interest from pharmaceutical groups, health systems and consumer health conglomerates. The 2025 BCG X survey highlighted that only 41% of women believed sufficient health services existed for their concerns, a TAM signal that strategic buyers find compelling.

M&A dynamics in FemTech mirror the broader sector shift: fertility platforms (IVI, FutureLife) have established consolidation playbooks through PE-backed roll-ups of regional clinic networks. FutureLife's 2024 acquisition of Bristol-based BCRM expanded its UK regional presence beyond London in a landmark deal. Phoenix PE invested in London Gynaecology in 2024, targeting scaling of private gynaecology care against long NHS waiting times. Flo Health's unicorn valuation in 2024 as the first women's health unicorn established benchmark valuations for digital FemTech platforms.

The advisory opportunity in FemTech is compounded by the historically low analyst coverage: most generalist investment banks lack dedicated FemTech practices, creating a significant gap that specialist advisors fill.

Founder Bankers with direct experience in women's health, consumer health or adjacent clinical areas carry immediate credibility with both founders (who often have personal motivations for building in the space) and acquirers (who need to understand clinical outcome differentiation).

Healthcare AI

Healthcare AI has emerged as the fastest-growing and most contested sub-sector in European HealthTech M&A. The top-funded sub-sectors in European HealthTech H1 2025 were drug discovery (including TechBio using AI/bioinformatics), medical diagnostics (AI-driven radiology and pathology) and digital health platforms with embedded AI.

Three acquisition playbooks are consolidating the Healthcare AI landscape:

Platform Acquisitions — Corporate buyers acquiring AI-rich assets to embed decision support across care pathways and accelerate digital transformation
AI-Native Roll-Ups — PE-backed mergers of traditional healthcare software businesses with AI start-ups, creating scaled platforms with differentiated data and automation
Regulatory Arbitrage Consolidation — EU MDR/IVDR, EU AI Act and EHDS raising the compliance bar, pushing sub-scale SMEs into better-capitalised consolidators

The advisory challenge in Healthcare AI is the most technically demanding in the sector: distinguishing between genuinely clinical AI (with validated algorithms, real-world evidence, EHR integration and a regulatory pathway) and AI-adjacent marketing requires deep technical diligence that generalist advisors are often poorly equipped to perform.

Founder Bankers who have built or operated clinical AI products understand the difference between a demo and a deployed system, and can translate that distinction into valuation arguments that hold up under buyer scrutiny.

Part V: The Advisory Market Landscape, Specialists vs. Generalists, The League Table Reconfigured

The advisory market for European healthcare M&A is best understood as segmented by deal size and asset complexity, rather than simply by advisory prestige:

Advisor	Primary Strength	Deal Size Sweet Spot	Key Sub-sectors
Goldman Sachs	Large-cap exits, IPOs ($97.5bn+ value, 2024)	€500M+	Mega-deals, public M&A
Rothschild & Co	Mid-market ubiquity, PE relationships (132 deals, 2024)	€100M–€2bn	Broad mid-market healthcare
J.P. Morgan	Complex cross-border strategic M&A	€500M+	Large-cap pharma, MedTech
Morgan Stanley	Financial sponsor relationships	€200M+	PE-backed platforms
Arma Partners	Digital Health, SaaS, Healthcare IT	€20M–€500M	Digital health, tech-enabled care
Nelson Advisors	Founder-led exits, Healthcare AI	€25M–€200M	HealthTech, MedTech, AI, FemTech
Clipperton	High-growth Tech/SaaS-in-healthcare	€10M–€300M	Digital health, SaaS platforms
Van Lanschot Kempen	Biotech, Diagnostics, Life Sciences	€50M–€500M	MedTech, biotech, diagnostics

The critical insight from this segmentation is that the competitive gap is not between bulge-bracket and boutique in terms of capability, it is between generic and specialised in terms of relevance to the asset.

For a founder-led healthcare AI company with €15M ARR seeking a strategic exit, Goldman Sachs is not the natural advisor: they will not have a dedicated partner who understands AI Act compliance implications for valuation, can credibly articulate clinical validation to a NHS procurement-aware buyer, or empathise with the psychological complexity of a founder's first liquidity event.

Even generalist mega-firms have acknowledged this dynamic.

Goldman Sachs has been cited as hiring medical doctors to lead its EMEA healthcare teams, recognising that bio-technical diligence in Healthcare AI requires clinical depth, not purely financial acuity. This is itself evidence of the structural shift the Founder Banker embodies.

The Consolidation of Advisory Firms

The boutique advisory ecosystem is itself undergoing consolidation. Stifel's acquisition of Bryan Garnier and Houlihan Lokey's European healthcare expansion signal a maturing mid-market where successful specialist advisory firms are becoming acquisition targets for larger institutions seeking domain expertise.

This dynamic validates the model: the value being created by specialist boutiques is real enough that larger platforms are acquiring it rather than building it organically.

Part VI: Due Diligence Evolution, The Founder Banker's Operational Contribution, Beyond the Information Memorandum

The Founder Banker's value is most tangible in the diligence and process phases of a transaction. Modern healthcare technology M&A diligence in 2026 extends far beyond financial review into technical architecture audits, regulatory compliance assessments, clinical evidence evaluation and integration planning, each requiring expertise that traditional investment bankers lack.

Key diligence areas where Founder Bankers provide differential value:

Diligence Focus	2026 Requirement	Where Founder Bankers Add Value
Model Architecture	GPAI compliance; AI Act transparency obligations	Distinguishing genuinely interpretable AI from marketing claims
Data Provenance	Audit of training datasets; IP provenance	Understanding real-world data collection practices vs. theoretical claims
Clinical Validation	Real-world evidence; RCT vs. retrospective data	Assessing clinical evidence quality and reimbursement implications
Regulatory Status	MDR certificates; AI Act audit readiness	Translating regulatory certificates into valuation premiums
Integration Reality	EHR/legacy stack compatibility; CIO skepticism	Managing acquirer expectations based on first-hand integration experience

AI-Augmented Advisory

Ironically, Healthcare AI is also reshaping the advisory process itself. AI-driven due diligence tools are enabling faster deal evaluations and superior risk detection through automated document review and machine learning-powered pattern recognition. Automated lease analysis has become 70% faster and error rates in compliance checks have dropped by 40% through AI-powered tools, changing the economics and speed of deal execution.

Founder Bankers who embrace these tools can maintain quality while significantly improving deal velocity, a competitive advantage in auction processes where speed of diligence often determines mandate retention.

Part VII: Strategic Recommendations and Outlook, For Founders Preparing for Exit

The advisory selection decision is now strategic, not simply administrative. The choice between a generalist firm and a Founder Banker boutique should be driven by asset complexity, buyer universe, and the specific technical or regulatory narrative that needs to be constructed and defended.

Prioritise clinical utility narrative: In 2026, value is determined by integration into clinical pathways and measurable ROI for health systems, advisors must be able to construct and defend this narrative with technical credibility
Treat regulatory assets as financial assets: MDR certificates, AI Act compliance documentation and EUDAMED registration are valuation levers, not administrative formalities, advisors who understand this translate compliance investment into premium multiples
Align with Rule of 40 benchmarking: The primary financial metric for commanding premium multiple is the Rule of 40, advisors should help prepare companies to present against this benchmark, including clarity on path to profitability
Leverage transatlantic buyer intelligence: US acquirers participated in 62% of late-stage European deals in 2025; advisors with direct US relationships and cross-border execution experience are essential for competitive processes

For Strategic Acquirers and PE Sponsors

The Founder Banker model also changes how buyers should structure their advisory relationships. Buy-side M&A in HealthTech increasingly requires advisors who can assess operational reality, not just financial metrics, to avoid overpaying for technically impressive but commercially fragile assets.

The three dominant acquisition playbooks for 2026, platform consolidation, AI-native roll-ups, and regulatory arbitrage, each require a different type of advisor expertise that the generalist advisory model struggles to provide at the sub-€500M tier.

Market Outlook: 2026–2027

The European HealthTech market is valued at approximately $96.68 Billion in 2025 and projected to reach $222.22 Billion by 2030. Against this backdrop, several trends are likely to define the advisory landscape over the next 18–24 months:

Continued bifurcation: The gap between premium AI-validated assets and undifferentiated point solutions will widen further, increasing the valuation sensitivity to advisory quality
Distressed M&A expansion: The convergence of MDR/IVDR enforcement, EU AI Act obligations and PE exit pressure will accelerate distressed M&A as undercapitalised firms are forced to sell
FemTech institutionalisation: As FemTech matures from niche to mainstream acquisition target, demand for advisors with specific women's health expertise will intensify
Healthcare AI commoditisation risk: As more companies claim AI capabilities, the premium for genuine clinical AI will concentrate in a smaller number of genuinely differentiated assets, creating advisory mandate opportunities for specialists who can credibly separate signal from noise
Founder Banker model replication: The success of the pioneer Founder Banker model will attract imitation; the differentiation will increasingly shift to quality of exits, sector depth, and specific sub-sector specialisation (e.g., FemTech vs. surgical robotics vs. clinical AI) rather than the generic "founder background" credential alone

Conclusion

The emergence of the Founder Banker in European healthcare M&A is not a cyclical phenomenon or a niche trend, it is a structural recalibration of the advisory market to match the irreducible complexity of 2026's healthcare technology assets.

When regulatory compliance determines enterprise value, when clinical validation is the primary M&A diligence question, and when the psychological complexity of founder exits requires advisors who have navigated them personally, the traditional linear career path of the investment banker is an insufficient preparation for the advisory role.

The Great Rationalisation has made this mismatch visible. The firms and individuals who built their advisory practices on operational pedigree, Nelson Advisors, Arma Partners, Clipperton, ConAlliance, have found themselves structurally advantaged in precisely the market environment that 2026 has produced.

The measure of this model's success will be its proof through exits: not the size of deals in the press release, but the quality of outcomes for founders, investors and health systems that trusted them with the most consequential decisions of their professional lives.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech